Magnesium in atherosclerotic cardiovascular disease and sudden death

Acta Cardiologica
|January 1, 1981
PubMed

Insights

Magnesium is vital for heart health, preventing sudden cardiac death and heart attacks. Supplementing magnesium may protect the heart from damage and electrical instability.

Area of Science:

  • Cardiology
  • Biochemistry
  • Electrophysiology

Background:

  • Magnesium ions are crucial for myocardial function and structure.
  • Epidemiological studies link low magnesium to sudden cardiac death and heart attack risk.
  • Infarcted myocardium shows reduced magnesium levels compared to healthy tissue.

Purpose of the Study:

  • To explore the role of magnesium in myocardial ischemia and sudden cardiac death.
  • To investigate the cardioprotective effects of magnesium.
  • To assess the therapeutic and prophylactic value of magnesium in cardiovascular disease.

Main Methods:

  • Review of epidemiological studies and recent research on magnesium's role in the myocardium.
  • Analysis of magnesium's metabolic, biochemical, and electrophysiological effects.
  • Consideration of magnesium's interaction with ion channels and cellular processes.

Main Results:

  • Magnesium deficiency sensitizes the myocardium to toxins and hypoxia, while magnesium administration is protective.
  • Magnesium acts as a co-enzyme, activating adenosine-triphosphatase, and may counteract inhibition by lactate and free fatty acids.
  • Magnesium deficiency is implicated in chronic electrical instability, predisposing to sudden cardiac death.

Conclusions:

  • Magnesium plays a significant role in treating myocardial ischemia.
  • Evidence supports the use of magnesium salts for preventing ischemic heart disease and sudden cardiac death.
  • Magnesium is cardioprotective, influencing action potential duration and membrane potential, but its full therapeutic value requires further assessment.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...